Latest revenue
$0
as of 2026-03-31
Latest net income
$-102.3M
as of 2026-03-31
Net margin
—
as of 2026-03-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Community sentiment
Where do you think XENE is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $5.00B
- Enterprise value
- $4.47B
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 3.74×
- Dividend yield
- —
- 52-wk high
- —
- 52-wk low
- —
- Beta
- —
- Shares out
- 96.7M
5-year trend
What this company does
Item 1. Business We are a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need. We are advancing a differentiated product pipeline led by our investigational candidate, azetukalner, which is being studied in multiple Phase 3 studies in epilepsy, major depressive disorder, or MDD, and bipolar depression, or BPD. Our early-stage pipeline includes Kv7 potassium channel openers and Nav sodium channel modulators being advanced for select high‑need indications, including pain. Our Strategy Our goal is to build a fully-integrated and profitable biopharmaceutical company that…
AI summary unavailable — showing raw filing excerpt
Generated from XENE's filing dated 2026-02-26
Key risks
Item 1A. Risk Factors You should carefully consider the following risk factors, in addition to the other information contained in this report, including the section of this report captioned “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our financial statements and related notes. If any of the events described in the following risk factors and the risks described elsewhere in this report occurs, our business, operating results and financial condition could be seriously harmed. This report on Form 10-K also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in…
AI summary unavailable — showing raw filing excerpt
Generated from XENE's filing dated 2026-02-26
Profitability
Operating margin
-4974.3%
263.4%Net margin
-4612.1%
247.1%Return on equity
-59.5%
91.6%Return on assets
-54.6%
86.1%Leverage
Debt / equity
0.09×
54.3%Debt / assets
8.1%
49.9%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $0 | -100.0% | $-102.3M | -57.3% | — |
Q4 2025 2025-12-31 | $0 | — | $-105.3M | -60.3% | — |
Q3 2025 2025-09-30 | $0 | — | $-90.9M | -44.8% | — |
Q2 2025 2025-06-30 | $0 | — | $-84.7M | -46.2% | — |
Q1 2025 2025-03-31 | $7.5M | — | $-65.0M | -35.7% | -867.3% |
Q4 2024 2024-12-31 | $0 | — | $-65.7M | — | — |
Q3 2024 2024-09-30 | $0 | — | $-62.8M | -29.6% | — |
Q2 2024 2024-06-30 | $0 | — | $-57.9M | -22.0% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on XENE — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$21.8M
Net activity
−$21.8M
Distinct insiders
3
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns XENE
Institutional value
$1.39B
Total shares held
24.2M
Distinct holders
143
-102 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 5.6M | $328.0M | +539.8K (+10.6%) | Added |
| 2 | Capital International Investors | 2.7M | $155.5M | -740.2K (-21.7%) | Trimmed |
| 3 | JPMORGAN CHASE & CO | 1.9M | $106.9M | +429.6K (+28.8%) | Added |
| 4 | WESTFIELD CAPITAL MANAGEMENT CO LP | 1.4M | $81.5M | +174.7K (+14.2%) | Added |
| 5 | JENNISON ASSOCIATES LLC | 1.3M | $76.7M | +26.8K (+2.1%) | Added |
| 6 | FRANKLIN RESOURCES INC | 1.3M | $74.5M | +522.5K (+68.9%) | Added |
| 7 | FEDERATED HERMES, INC. | 972.2K | $56.5M | +300.0K (+44.6%) | Added |
| 8 | Capital World Investors | 840.1K | $48.9M | +184.3K (+28.1%) | Added |
| 9 | Fiera Capital Corp | 709.5K | $41.3M | +23.5K (+3.4%) | Added |
| 10 | Pictet Asset Management Holding SA | 679.7K | $39.2M | +53.7K (+8.6%) | Added |
| 11 | abrdn plc | 609.9K | $35.5M | -140.4K (-18.7%) | Trimmed |
| 12 | VANGUARD PORTFOLIO MANAGEMENT LLC | 543.1K | $31.6M | — | New |
| 13 | Candriam S.C.A. | 476.5K | $27.7M | -358.3K (-42.9%) | Trimmed |
| 14 | Bank of New York Mellon Corp | 396.1K | $23.0M | +9.0K (+2.3%) | Added |
| 15 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 375.2K | $21.8M | +374.9K (+158868.6%) | Added |
| 16 | TimesSquare Capital Management, LLC | 359.3K | $20.9M | -173.4K (-32.6%) | Trimmed |
| 17 | Nuveen, LLC | 250.0K | $14.5M | +33.8K (+15.6%) | Added |
| 18 | NAN FUNG TRINITY (HK) LTD | 247.8K | $14.4M | +20.8K (+9.2%) | Added |
| 19 | Allspring Global Investments Holdings, LLC | 246.3K | $14.0M | — | New |
| 20 | NEW YORK STATE COMMON RETIREMENT FUND | 188.5K | $11.0M | +1.8K (+1.0%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once XENE's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.